{"title":"骨质疏松症的抗吸收治疗。","authors":"Konstantin Horas, Andreas Kurth","doi":"10.1007/s00132-025-04725-5","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoporosis is a systemic skeletal disorder that is characterised by low bone mineral density (BMD) and deterioration of bone tissue. Eventually, this leads to disruption of bone microarchitecture, a compromised bone strength and an increase risk of fracture. Antiresorptive therapies are used to increase bone strength and reduce the risk of fracture in individuals with osteoporosis. The most common antiresorptives are bisphosphonates, estrogens, selective estrogen receptor modulators (SERM) and the human monoclonal antibody against RANKL (Denosumab).</p>","PeriodicalId":74375,"journal":{"name":"Orthopadie (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Antiresorptive therapies in osteoporosis].\",\"authors\":\"Konstantin Horas, Andreas Kurth\",\"doi\":\"10.1007/s00132-025-04725-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Osteoporosis is a systemic skeletal disorder that is characterised by low bone mineral density (BMD) and deterioration of bone tissue. Eventually, this leads to disruption of bone microarchitecture, a compromised bone strength and an increase risk of fracture. Antiresorptive therapies are used to increase bone strength and reduce the risk of fracture in individuals with osteoporosis. The most common antiresorptives are bisphosphonates, estrogens, selective estrogen receptor modulators (SERM) and the human monoclonal antibody against RANKL (Denosumab).</p>\",\"PeriodicalId\":74375,\"journal\":{\"name\":\"Orthopadie (Heidelberg, Germany)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Orthopadie (Heidelberg, Germany)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00132-025-04725-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orthopadie (Heidelberg, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00132-025-04725-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Osteoporosis is a systemic skeletal disorder that is characterised by low bone mineral density (BMD) and deterioration of bone tissue. Eventually, this leads to disruption of bone microarchitecture, a compromised bone strength and an increase risk of fracture. Antiresorptive therapies are used to increase bone strength and reduce the risk of fracture in individuals with osteoporosis. The most common antiresorptives are bisphosphonates, estrogens, selective estrogen receptor modulators (SERM) and the human monoclonal antibody against RANKL (Denosumab).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
